Research programme: anti-complement monoclonal antibodies - Alexion AstraZeneca Rare Disease
Alternative Names: 133.3 - Alexion; Anti C5 monoclonal antibody BB5-1 - Alexion; Anti-C8-monoclonal-antibody - Alexion; Monoclonal antibody N19/8 - Alexion; N19/8 - AlexionLatest Information Update: 29 Jul 2021
At a glance
- Originator Alexion Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Complement C5 inhibitors; Complement C8 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Idiopathic thrombocytopenic purpura; Xenotransplant rejection
Most Recent Events
- 21 Jul 2021 Alexion Pharmaceuticals has been acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease
- 15 Dec 2000 Preclinical development for Idiopathic thrombocytopenic purpura in USA (Unknown route)